BOOST Pharma: Difference between revisions
Updated |
Added valuation: €3.1M+ (Nov 2025); est. ~€5-15M |
||
| Line 11: | Line 11: | ||
== Funding == | == Funding == | ||
'''Valuation:''' €3.1M+ (Nov 2025); est. ~€5-15M | |||
€3.1 million additional funding (November 2025).<ref>EU-Startups (Nov 3, 2025): "In bid to improve outcomes for children with genetic bone disease, Swedish startup BOOST Pharma raises additional €3.1 million"</ref> | €3.1 million additional funding (November 2025).<ref>EU-Startups (Nov 3, 2025): "In bid to improve outcomes for children with genetic bone disease, Swedish startup BOOST Pharma raises additional €3.1 million"</ref> | ||
Latest revision as of 07:42, 14 April 2026
What They Do[edit]
Cell therapy for children with osteogenesis imperfecta (genetic bone disease / brittle bone disease).
Funding[edit]
Valuation: €3.1M+ (Nov 2025); est. ~€5-15M €3.1 million additional funding (November 2025).[1]
Traction[edit]
Strategic manufacturing agreement with RoslinCT for cell therapy production.[2]